Clinical Trial Update: Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib (BAY 43-9006) for recurrent/metastatic head and neck cancer reports on its efficacy and activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Head and Neck Neoplasms | Phase 2 | Status: COMPLETED